Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
Roche Holding AG - Key Company Facts 9
Roche Holding AG - Company Description 10
Roche Holding AG - Top Executives 11
Roche Holding AG- Top Executives Biographies 12
Roche Holding AG- Head Office & Locations 16
Head Office - Country 16
Key Subsidiaries 17
Roche Holding AG - Products and Services 20
Products 20
Services 21
Roche Holding AG - Historic Events 22
Roche Holding AG - Company’s Management Discussion 24
Roche Holding AG - Company’s Mission and Vision 27
Mission 27
Roche Holding AG - Corporate Strategy 28
Roche Holding AG - Business Description 33
Pharmaceuticals Division 34
Diagnostics Division 34
Roche Holding AG - ESG Spotlight 36
Environment 38
Social 38
Corporate Governance 39
Roche Holding AG - SWOT Analysis 40
Overview 40
Strengths 42
Weaknesses 45
Opportunities 47
Threats 49
Roche Holding AG - PESTLE Analysis 51
Overview 51
Political Factors 53
Economic Factors 55
Social Factors 57
Technological Factors 59
Legal Factors 60
Environmental Factors 62
Roche Holding AG - Financial Deep Dive 63
Share Price Trend - Oct-2023to Oct-2024 (Average Share Closing Price) 63
Profit and Loss Statement 65
Summary of Profit and Loss Statement 65
Balance Sheet 67
Summary of Balance Sheet 67
Cash Flow Statement 69
Summary of Cash Flow Statement 69
Key Financial Ratio Analysis 71
Roche Holding AG - Ratio Charts 72
Activity Ratio Charts 72
Growth Ratios Charts 73
Leverage Ratio Charts 74
Liquidity Ratio Charts 74
Profitability Ratio Charts 76
Competing Players 77
Snapshot of Competing Players 78
AbbVie Inc 78
Key Company Facts 78
Company Description 78
Snapshot of Competing Players 80
Bristol-Myers Squibb Company 80
Key Company Facts 80
Company Description 80
Snapshot of Competing Players 82
Eli Lilly and Company 82
Key Company Facts 82
Company Description 82
Snapshot of Competing Players 84
GSK plc 84
Key Company Facts 84
Company Description 84
Snapshot of Competing Players 86
Johnson & Johnson 86
Key Company Facts 86
Company Description 86
Snapshot of Competing Players 88
Merck KGaA 88
Key Company Facts 88
Company Description 88
Snapshot of Competing Players 90
Novartis AG 90
Key Company Facts 90
Company Description 90
Snapshot of Competing Players 92
Pfizer Inc. 92
Key Company Facts 92
Company Description 92
Snapshot of Competing Players 94
Sanofi SA 94
Key Company Facts 94
Company Description 94
Roche Holding AG - In the News 96
26-Sep-2024- Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis 96
24-Sep-2024- Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses 98
23-Sep-2024- WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions 100
19-Sep-2024- Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses 101
16-Sep-2024- FDA approves OCREVUS ZUNOVO as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis 102
07-Sep-2023- Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease 104
29-Aug-2023- European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA) 105
11-Jul-2023- European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma 106
09-May-2023- FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) 109
26-Apr-2023- CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma 110
16-Apr-2023- Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study 113
23-Feb-2023- Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer 114
01-Feb-2023- European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU 115
06-Jan-2023- FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma 116
13-Jun-2013- Roche awarded WHO prequalification for the cobas? HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries 118
Roche Holding AG- Key Deals 119
07-Sep-2022 - Roche snaps up PD-1-focused Good Therapeutics for $250M; ’Sky’s the limit’ for spinout 119
02-Dec-2021 - Roche acquires test maker TIB Molbiol 120
15-Sep-2021 - Roche Acquires TIB Molbiol to Boost Molecular Diagnostics Profile 120
15-Mar-2021 - Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample 122
24-Sep-2020 - Roche buys Inflazome for $445 million 122
16-Sep-2020 - Roche acquires Kapa Biosystems 124
17-Dec-2019 - The Wait Is Over: After Multiple Delays, Roche Completes Acquisition of Spark Therapeutics 124
25-Feb-2019 - Spark Therapeutics Enters into Definitive Merger Agreement with Roche 125
25-Feb-2019 - Roche acquires Spark in $4.8B gene therapy play 126
07-Apr-2018 - Roche Completes Acquisition of Flatiron Health 127
Appendix 128
Definitions 128
SWOT Analysis 128
PESTLE Analysis 128
Value Chain Analysis 128
ESG Spotlight 128
Financial Deep Dive 128
Financial Ratios - 129
Activity Ratios 129
Growth Ratios 130
Leverage Ratios 131
Liquidity Ratios 132
Market Ratios 133
Profitability Ratios 133
Research Methodology 134
Disclaimer 135
Contact Us 135



List of Figures

Charts
Figure 1: Roche Holding AG- SWOT Analysis 41
Figure 2: Roche Holding AG - PESTLE Analysis 52
Figure 3: Roche Holding AG - Average Share Price Trend - Oct-2023 to Oct-2024 64
Figure 4: Roche Holding AG - Profit and Loss Statement - 2020-2023 66
Figure 5: Roche Holding AG - Balance Sheet - 2020-2023 68
Figure 6: Roche Holding AG - Cash Flow Statement 2020-2023 70
Figure 7: Roche Holding AG - Activity Ratio Charts 72
Figure 8: Roche Holding AG - Growth Ratio Charts (Value %) 73
Figure 9: Roche Holding AG - Leverage Ratio Charts 74
Figure 10: Roche Holding AG - Liquidity Ratio Charts 75
Figure 11: Roche Holding AG - Profitability Ratio Charts (Value %) 76
Figure 12: Competing Players - AbbVie Inc - Key Financials 79
Figure 13: Competing Players - Bristol-Myers Squibb Company - Key Financials 81
Figure 14: Competing Players - Eli Lilly and Company - Key Financials 83
Figure 15: Competing Players - GSK plc - Key Financials 85
Figure 16: Competing Players - Johnson & Johnson - Key Financials 87
Figure 17: Competing Players - Merck KGaA - Key Financials 89
Figure 18: Competing Players - Novartis AG - Key Financials 91
Figure 19: Competing Players - Pfizer Inc. - Key Financials 93
Figure 20: Competing Players - Sanofi SA - Key Financials 95

List of Tables

Tables
Table 1: Roche Holding AG - Company Facts
Table 2: Roche Holding AG - Top Executives
Table 3: Roche Holding AG - Top Executives Biographies
Table 4: Roche Holding AG - Subsidiaries
Table 5: Roche Holding AG - Products
Table 6: Roche Holding AG - Services
Table 7: Roche Holding AG - Historic Events
Table 8: Roche Holding AG - Share Price Trend - Oct-2023 to Oct-2024
Table 9: Roche Holding AG- Ratio Analysis - 2020-2023
Table 10: Roche Holding AG -Competing Players